Latest Conference Coverage

Amyloid Copathology Not a Factor in Pharmacodynamic Effect of Irsenontrine in Dementia With Lewy Bodies, Parkinson Disease Dementia

Over a 12-week treatment period, irsenontrine was well tolerated across both amyloid positive and negative patients, with no significant difference in pharmacodynamic responses or change in central nervous system biomarkers.

Targeting Inflammation to Reduce Effects of Alzheimer Disease: RJ Tesi, MD

The president and chief executive officer of INmune Bio detailed the mechanistic advantages of XPro1595 as a potentially therapeutic benefit for patients with Alzheimer disease and dementia. [WATCH TIME: 5 minutes]

Donanemab Shows Greater Ability to Clear Amyloid Plaque Than Aducanumab

Over a 6-month period, percent change and mean change in brain amyloid levels significantly favored donanemab over aducanumab (Aduhelm; Biogen).

ACI-35.030 and JACI-35.054 Vaccinations Demonstrate Safety in Early Alzheimer Disease

An ongoing phase 1b/2a clinical trial showed that both the ACI-35.030 and JACI-35.054 vaccines are safe as a treatment for patients in the earlier stages of Alzheimer disease, the authors suggested ACI-35.030 suggested as the superior vaccine candidate.

NeuroVoices: Carrie Hersh, DO, MSc, on Applying 2-Stage Models to Improve Disease-Modifying Therapy Selection in MS

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided background on incorporation of real-world methods to optimize treatment selection for multiple sclerosis.

Lecanemab Represents Promising Therapy for Alzheimer Disease, Posts Positive Phase 3 Secondary Analyses

In the pivotal phase 3 Clarity AD trial, lecanemab (Biogen) demonstrated significant impacts on primary and secondary end points, with additional promising results on biomarker analyses and safety.

Digital Treatment Approach May Help Reduce Healthcare Burden for MS Fatigue: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College London spoke at ECTRIMS 2022 about the digital approach to treating fatigue in multiple sclerosis and the lack of available measurements. [WATCH TIME: 3 minutes]

NeurologyLive® Brain Games: November 27, 2022

CBT as an Effective Mood Therapy for Patients with MS Experiencing Fatigue: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the relationship between mood and fatigue in patients with MS. [WATCH TIME: 2 minutes]

Future Thoughts on Improving MS Trial Design, Calculations: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine provided perspective on how the clinical community can improve trials for multiple sclerosis that help improve treatment decisions. [WATCH TIME: 4 minutes]

Physical Movement Improves Fatigue for Patients with MS: Federica Picariello, PhD

The postdoctoral researcher and health psychologist at King's College, London spoke at ECTRIMS 2022 about the most important aspect for improving fatigue in MS. [WATCH TIME: 4 minutes]

NeurologyLive® Brain Games: November 20, 2022

Differences in Effective Therapies for Pediatric versus Adults with MS: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about the difference in conversation for therapies between pediatric patients and adult patients with MS. [WATCH TIME: 5 minutes]

Music-based Application Provides Nonpharmacological Approach to Improving Sleep in Alzheimer Disease

Darina Petrovsky, PhD, RN, assistant professor, Rutgers University, spoke about her current study focused on developing a music-based application for people with dementia and their caregivers who have trouble sleeping.

Living an Inspirational Life With Pediatric MS: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke at ECTRIMS 2022 about how her patients with pediatric MS have been inspirational to her in her practice. [WATCH TIME: 4 minutes]

Expanding the Clinical Application of 2-Stage Models for Heterogenous Treatment Effects in MS: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine detailed the next steps in reforming and applying new 2-stage models that improve selection for MS disease-modifying therapies. [WATCH TIME: 6 minutes]

Advantages of Wellness as a Therapy for Pediatric MS: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia, spoke about the wellbeing of pediatric patients with MS in reference to her presentation at ECTRIMS 2022. [WATCH TIME: 4 minutes]

Beginning and Transitioning DMT in MS: Dalia Rotstein, MD, MPH

The assistant professor of medicine at University of Toronto, and neurologist at St. Michael's Hospital spoke about the process of changing or beginning treatment with a variety of disease-modifying therapies in multiple sclerosis. [WATCH TIME: 4 minutes]

Gantenerumab Fails to Meet End Points in Initial GRADUATE Study Data

The GRADUATE studies, which spanned across 32 countries, showed minimal relative reduction in clinical decline for those on gantenerumab relative to placebo over a 116-week treatment cycle.

Establishing a Proof Of Concept Model to Improve MS Treatment Optimization: Carrie Hersh, DO, MSc

The associate professor of neurology at the Cleveland Clinic Lerner College of Medicine offered insight on her presentation at ECTRIMS 2022 looking at 2-stage models to better understand heterogeneous treatment effects of MS DMTs. [WATCH TIME: 6 minutes]

NeurologyLive® Brain Games: November 13, 2022

ALS Research on Genetic Testing and Counseling Provides Evidence-Based Consensus Guidelines for Clinicians

Jennifer Roggenbuck, MS, LGC, an associate professor of neurology and internal medicine at The Ohio State University Wexner Medical Center, discussed her presentation on evidence-based consensus guidelines for genetic testing and counseling from the 2022 NEALS Consortium.

Ability of Nuedexta to Improve Bulbar Function in Swallowing and Speech in ALS

James Wymer, MD, FAAN, discussed his presentation at the 2022 Annual NEALS meeting on improving speech and swallowing using Neudexta for patients with ALS.

Critical Takeaways, Learning Experiences From the Tofersen Trials in ALS: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine provided perspective on the lessons learned from the trials of tofersen, as it aims to become the first FDA-approved therapy specific to SOD1 ALS. [WATCH TIME: 4 minutes]

Single Dose of AstroRx Transplantation Cells Shown to be Safe for ALS

A phase 1/2a clinical trial resulted in showing that a single dosing of AstroRx was safe and tolerable, at either a low or high dose, for patients with ALS.

Progress for Patients With Pediatric MS, Fingolimod's Risk-Benefit Profile: Brenda Banwell, MD

The chief of neurology and codirector of the neuroscience Center at the Children's Hospital of Philadelphia spoke about her presentation at ECTRIMS 2022 on the treatment of pediatric MS. [WATCH TIME: 5 minutes]

Role of Tofersen Among Other Previously Approved ALS Therapies: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine in St. Louis provided background on how tofersen would be used alongside other ALS medications if approved. [WATCH TIME: 3 minutes]

Institutional Perspectives in Neurology, Chaired by Robert T. Naismith, MD

Chaired by Robert T. Naismith, MD, of Washington University in St. Louis, the presentations also feature Salim Chahin, MD, MSCE; Anne H. Cross, MD; Gregory F. Wu, MD, PhD; and Matthew R. Brier, MD, PhD. [WATCH TIME: 1 hour, 55 minutes]

NurOwn Stromal Cell Therapy Continues to Show Positive Data in Less Severe ALS

After removing participants at higher risk of reaching a floor effect of the ALSFRS-R, those treated with NurOwn demonstrated a higher rate of clinical response and less function lost across 28 weeks than placebo.

Understanding Tofersen’s Impact on SOD1 ALS, Neurofilament Light: Timothy Miller, MD, PhD

The codirector of the ALS Center at Washington University School of Medicine in St. Louis discussed the long-term data of VALOR and its open-label extension assessing tofersen (Biogen) in SOD1 ALS. [WATCH TIME: 4 minutes]